Panagariya A, Sharma A K
Dept. of Neurology, SMS Medical College and Hospital, Jaipur.
J Assoc Physicians India. 1999 Dec;47(12):1170-2.
This study was planned to assess the response of serratiopeptidase in patients with carpal tunnel syndrome (CTS).
Twenty patients with CTS were evaluated clinically. After baseline electrophysiological studies, these patients were given serratiopeptidase 10 mg twice daily with initial short course of nimesulide. Clinical and electrophysiological reassessment was done after 6 weeks.
Mean age was 43.9 years with male to female ratio of 1:2.33. Sixty five percent cases showed significant clinical improvement which was supported by significant improvement in electrophysiological parameters. Recurrence was reported in four cases. No significant side effect was observed.
Serratiopeptidase therapy may proved to be a useful alternative mode of conservative treatment. Larger study may be further helpful to establish the role of serratiopeptidase in CTS.
本研究旨在评估舍雷肽酶对腕管综合征（CTS）患者的疗效。
对20例CTS患者进行临床评估。在进行基线电生理研究后，给予这些患者舍雷肽酶，每日两次，每次10毫克，并初始短期服用尼美舒利。6周后进行临床和电生理重新评估。
平均年龄为43.9岁，男女比例为1:2.33。65%的病例显示出显著的临床改善，电生理参数也有显著改善作为支持。有4例报告复发。未观察到明显副作用。
舍雷肽酶治疗可能被证明是一种有用的保守治疗替代方式。更大规模的研究可能有助于进一步确立舍雷肽酶在CTS中的作用。
